MedImmune Appoints Development Leadership Team
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Cambridge Antibody Technology exec to oversee product development.
You may also be interested in...
AstraZeneca Concentrates Biologics At MedImmune, Ups R&D
MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.
AstraZeneca Hears CAT’s Meow With Biotech Acquisition
Deal for Cambridge Antibody Technology, valued at $1.07 bil., will shift focus of AstraZeneca’s pipeline.
A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen
Biogen has been granted new US patents for Tecfidera after generics already launched. It's unclear how Biogen will proceed but management could shed more light on the matter during the first quarter call.